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Cyclooxygenase-2 Inhibition Attenuates Abdominal
Aortic Aneurysm Progression in Hyperlipidemic Mice
Sarbani Ghoshal, Charles D. Loftin*
Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America

Abstract
Abdominal aortic aneurysms (AAAs) are a chronic inflammatory disease that increase the risk of life-threatening aortic
rupture. In humans, AAAs have been characterized by increased expression of cyclooxygenase-2 and the inactivation of
COX-2 prior to disease initiation reduces AAA incidence in a mouse model of the disease. The current study examined the
effectiveness of selective cyclooxygenase-2 (COX-2) inhibition on reducing AAA progression when administered after the
initiation of AAA formation. AAAs were induced in hyperlipidemic apolipoprotein E-deficient mice by chronic angiotensin II
(AngII) infusion and the effect of treatment with the COX-2 inhibitor celecoxib was examined when initiated at different
stages of the disease. Celecoxib treatment that was started 1 week after initiating AngII infusion reduced AAA incidence by
61% and significantly decreased AAA severity. Mice treated with celecoxib also showed significantly reduced aortic rupture
and mortality. Treatment with celecoxib that was started at a late stage of AAA development also significantly reduced AAA
incidence and severity. Celecoxib treatment significantly increased smooth muscle alpha-actin expression in the abdominal
aorta and did not reduce expression of markers of macrophage-dependent inflammation. These findings indicate that COX2 inhibitor treatment initiated after formation of AngII-induced AAAs effectively reduces progression of the disease in
hyperlipidemic mice.
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reduction in macrophage-dependent inflammation in the abdominal aorta at an early stage of the disease [4]. The inactivation of
microsomal prostaglandin E synthase-1 (mPGES-1) in mice prior
to initiation of the disease also results in reduced AAA incidence
and severity [5]. However, the mechanism for the effectiveness of
mPGES-1 deficiency does not result from attenuated macrophagedependent inflammation. Because mPGES-1 is primarily thought
to function down-stream of COX-2, the proinflammatory effects
of COX-2-derived prostanoids that function at an early stage of
AAA formation may be distinct from COX-2-dependent mechanisms contributing to later stage AAA progression. In the current
study, we report that inhibition of COX-2 with celecoxib shows
dramatic effectiveness for reducing AAA progression and aortic
rupture when treatment is first started well after initiation of the
disease. The effectiveness of COX-2 inhibition is not associated
with attenuated macrophage-dependent inflammation, but does
correlate with characteristics of increased SMC differentiation.

Introduction
Abdominal aortic aneurysms (AAAs) are a chronic condition
that often begin as minor vessel dilation that progresses over years
to produce a weakened aorta with increased susceptibility for
rupture. Although AAAs at all stages of progression are readily
detectable in humans by noninvasive imaging techniques, there
are no pharmacological treatments currently available to slow
progression at an early stage of the disease or cause regression of
fully-formed aneurysms. Approximately 80% of the small aneurysms that are detected eventually require surgical repair, which is
currently the only known successful form of treatment [1,2].
However, because of significant risk associated with surgical
repair, this treatment is considered acceptable only for those
patients diagnosed with the most severe form of the disease. The
characterization of mechanisms contributing to aortic aneurysmal
remodeling will facilitate identification of medications that are
effective for reducing progression when treatment is initiated after
diagnosis of the disease.
We previously identified cyclooxygenase-2 (COX-2) that is
expressed in smooth muscle cells (SMCs) of the abdominal aorta as
an important contributor to AAA development in a mouse model
of the disease. We showed that AAA incidence and severity that
was induced in mice by chronic infusion of angiotensin II (AngII)
were significantly reduced by pre-treatment with the COX-2
inhibitor celecoxib or by targeted genetic inactivation of COX-2
prior to initiating AngII infusion [3,4]. The effectiveness of COX2 inactivation prior to disease initiation was associated with a
PLOS ONE | www.plosone.org

Experimental Procedures
Animals
ApoE-deficient male mice on a C57BL/6J background strain
purchased from the Jackson Laboratories (Bar Harbor, Maine)
were allowed to age from 14–16 weeks before beginning each
study. For the studies that utilized an AngII infusion of 6 weeks,
osmotic pumps were implanted in mice at 4 months of age and
studies with an 8-week AngII infusion utilized 3.5 month-old mice.
Mice were housed under barrier conditions with food and water ad
1
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libitum. For subcutaneous osmotic pump implantation, mice were
anesthetized with isoflurane at a concentration of 2% in oxygen
that was delivered using a precision vaporizer and an induction
box. For performing euthanasia, mice were first anesthetized by
intraperitoneal injection of ketamine (100 mg/kg) and xylazine
(10 mg/kg) until unresponsive to pain, followed by thoracotomy
and exsanguination under anesthesia. All studies were conducted
under the approval of the University of Kentucky Institutional
Animal Care and Use Committee (approval No. 2008-0262) and
conform to the Guide for the Care and Use of Laboratory Animals
published by the National Institutes of Health (NIH Publication
No. 85–23, revised 1996).

Quantitation of mRNA Expression
Following euthanasia of the mice, the abdominal segment of the
aorta containing the region distal of the intercostal arteries to
below the renal arteries was excised and stored in RNALater
(Sigma). Total RNA was extracted from the abdominal segments
using RNeasy Mini kits (Qiagen). Quantitative gene expression
was performed in a two-step RT-PCR using Superscript II
(Invitrogen) and fluorogenic 59 nuclease chemistry (Taqman
Assays, Applied Biosystems). A ratio of expression level between
the mRNA of interest and the constitutively expressed housekeeping gene hypoxanthine phospho-ribosyl transferase (HPRT) was
quantified using manufacturers recommended PCR conditions
(Applied Biosystems) [4,7,8]. A standard curve from within each
PCR run was used for the relative standard curve method of
quantitating mRNA expression.

AngII Infusion
Mice were implanted with subcutaneous osmotic pumps (Alzet
model 2004 28-day delivery or model 2006 42-day delivery)
containing AngII (Sigma). AngII was infused at a rate of 1 mg/kg/
min for the 6-week infusion studies and 0.75 mg/kg/min for the 8week AngII infusions. For the 8-week AngII infusions, 28-day
delivery pumps (model 2004) were replaced with new pumps after
the first 4 weeks of infusion. The 0.75 mg/kg/min AngII infusion
rate for the 8-week study was used to allow for an acceptable level
of mortality during this prolonged continuous exposure to AngII.

Histological Analysis
Following euthanasia, cardiac puncture was performed to
perfuse the aorta with PBS and then 10% neutral buffered
formalin solution prior to collection for histological analysis.
Suprarenal abdominal aortas were processed in a dehydrating
ethanol gradient, followed by xylene incubation and paraffin
embedding. Eight micron sections were used for hematoxylin and
eosin (H&E) staining and immunohistochemical analysis of COX2 (primary antibody from Cayman Chemical) or smooth muscle aactin (Dako Cytomation). Hyaluronic acid was detected using
biotinylated hyaluronic acid binding protein (Calbiochem). Antibodies or hyaluronic acid binding protein was detected using
Vectastain Elite ABC kit (Vector Laboratories) and di-amino
benzidine staining using manufacturer’s instructions. Immunohistochemical sections were counterstained with hematoxylin.

Celecoxib Administration
Mice were provided normal laboratory diet (Harlan Teklad)
prior to replacing with a pelleted diet containing 1000 ppm
celecoxib (LKT Laboratories Inc.) or a matched control diet
(Purina 5002) that was pelleted without celecoxib (Research Diets,
Inc.). The 1000 ppm dose of celecoxib added to the diet has been
shown to not alter the weight of the mice or affect blood pressure
following AngII infusion [3]. We have reported previously, that
the 1000 ppm celecoxib concentration in the diet results in a
plasma concentration of approximately 1.6 mg/ml, which approximates the therapeutic plasma concentration of celecoxib in
humans [3,6]. For the study analyzing the effect of celecoxib
treatment beginning at early-stage of AAA progression, mice were
infused with 1 mg/kg/min of AngII, as described above, and after
1 week were either provided control diet or diet containing
celecoxib. The mice were then sacrificed for analysis after 6 weeks
of AngII infusion. For the study determining the effect of celecoxib
treatment beginning at late-stage AAA progression, mice were
infused with 0.75 mg/kg/min of AngII, as described above, and
after 3 weeks were either provided control diet or diet containing
celecoxib, followed by analysis after 8 weeks of AngII infusion.

Statistical Analyses
For analysis of AAAs and mRNA expression in the abdominal
aorta, tissue isolated from one individual mouse was considered as
an n of 1. Significant differences in incidence among different
groups was determined using Fisher’s exact test (Prism, GraphPad
Software Inc.). The mean and SEM were determined for aortic
diameter and mRNA expression and significant differences among
groups were determined using unpaired two-tailed t-test, with
differences being considered statistically significant at P,0.05.

Results
COX-2 inhibitor treatment initiated during early-stage
AAA progression reduces AAA incidence

Vascular Pathology

The infusion of AngII for 1 week in mice not treated with
celecoxib resulted in a 40% incidence of AAAs (Figure 1A). As
compared to the 1-week infusion, the AAA incidence was
significantly increased in control mice receiving AngII infusion
for 6 weeks (Figure 1A). For the celecoxib-treated mice, the COX2 inhibitor was started 7 days following the initiation of AngII
infusion and was continued throughout the remaining 5 weeks of
the infusion. As shown in Figure 1A, the 5 weeks of celecoxib
treatment significantly reduced AAA incidence when analyzed
after completion of the 6-week AngII infusion, as compared to
control mice not receiving celecoxib. These findings suggest that
beginning celecoxib treatment at an early-stage of the disease
reduces the increase in AAA incidence that occurs with continued
AngII infusion.

Following euthanasia, abdominal aortas of the mice were
surgically exposed for analysis. Aneurysms in the supra-renal
abdominal aorta were quantified by measuring the external
diameter using a dissecting microscope and a digital caliper
micrometer. Using this method of analysis under magnification,
aneurysmal pathology was readily detectable with an abdominal
aorta external diameter of 1.2 mm. Thus, the minimal diameter of
1.2 mm was used to designate the presence of an AAA. AAA
severity was determined as a measurement of the external
diameter and classified as Type 1: 1.2–2 mm or Type 2: 2–
3 mm. Rupture of the aorta was defined by the identification of
hematomas outside of the aorta in euthanized moribund mice or
following necropsy of dead mice. Similar to our previous studies,
mice that died prior to completion of the study as a result of aortic
rupture were not included in the AAA incidence and severity
calculations [4].
PLOS ONE | www.plosone.org
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Figure 1. COX-2 inhibitor treatment initiated 1 week after beginning AngII infusion effectively reduces AAA progression in ApoEdeficient mice. (A) AAA incidence was determined at necropsy following 1 (1 Wk AngII) or 6 weeks (Control and Celecoxib) of AngII infusion. (B) The
maximal external diameter or (C) AAA classification of the suprarenal aorta following 1 (1 Wk AngII) or 6 weeks (Control and Celecoxib) of AngII
infusion. (D) Incidence of aortic rupture in mice on control or celecoxib containing diet following 6 weeks of AngII infusion. (E) Survival of Control and
Celecoxib-treaded mice during the AngII infusion. (F) Representative image of postmortem detection of hemorrhage in the abdominal cavity
indicating aortic rupture. For aortic diameter, results depict mean 6 SEM. AAA incidence and diameter: 1 Wk AngII n = 10, Control n = 11, Celecoxib
n = 18; aortic rupture: Control n = 15, Celecoxib n = 18. P values were determined for incidence data using Fisher’s exact test and an unpaired twotailed t-test for aortic diameter. * indicates P,0.05, ** indicates P,0.01, *** indicates P,0.001.
doi:10.1371/journal.pone.0044369.g001

increase in AAA size, as compared to mice infused with AngII for
1 week, suggesting significant expansion of AAA severity during
the additional 5 weeks of the infusion. The administration of
celecoxib during the final 5 weeks of AngII infusion significantly
reduced the mean external diameter of the abdominal aorta, as
compared to mice on control diet infused with AngII for 6 weeks
(Figure 1B). Classification of the external diameter of the
abdominal aorta showed reduced severity of the vascular

COX-2 inhibitor treatment initiated during early-stage
AAA progression reduces AAA severity
AngII-induced AAAs are characterized by expansion of the
external diameter of the abdominal aorta [9]. The external
diameter of the abdominal aorta was compared between mice
infused with AngII for 1 week or 6 weeks. As shown in Figure 1B,
the infusion of AngII for 6 weeks (Control) resulted in a significant

PLOS ONE | www.plosone.org

3

November 2012 | Volume 7 | Issue 11 | e44369

Celecoxib Inhibits Aortic Aneurysm Progression

pathology in mice receiving celecoxib treatment (Figure 1C).
These findings indicate that celecoxib treatment is effective for
reducing AAA severity when initiated 1 week after beginning the
AngII infusion and suggests that the inhibition of COX-2 limits
the progression of early AAAs once they have formed.

COX-2 inhibitor treatment initiated during early-stage
AAA progression reduces aortic ruptur
The AngII infusion model of AAA development is associated
with a significant increase in mortality resulting from aortic
rupture [10]. In the current study, the effect on aortic rupture and
death was examined following celecoxib treatment that was
initiated 1 week after beginning a 6-week AngII infusion. The
incidence of aortic rupture and death that occurred during the
final 5 weeks of the AngII infusion was significantly lower in the
celecoxib treatment group, as compared to mice on control diet
(Figure 1D). The mortality in the control group occurred from
week 2 to week 4 of the AngII infusion (Figure 1E). Aortic rupture
was determined by the detection of blood adjacent to the aorta
following postmortem analysis of the thoracic and abdominal
cavity (Figure 1F). These findings indicate that celecoxib treatment
initiated 1 week after beginning the AngII infusion effectively
reduced aortic rupture and mortality.

COX-2 inhibitor treatment initiated during late-stage
AAA progression reduces AAA incidence
With our finding that celecoxib administration was effective
when beginning treatment early after AAA initiation, we also
examined celecoxib’s effect on fully-formed AAAs. For celecoxibtreated mice, drug administration was begun 3 weeks after
initiating the AngII infusion, and the AngII infusion for both
control diet and celecoxib diet groups was continued for a total of
8 weeks, at which time AAA development was examined. As
shown in Figure 2A, the celecoxib-treated mice showed a
significant reduction in AAA incidence, as compared to mice on
control diet (36% vs. 85% in the control mice). In order to estimate
the AAA incidence in mice at the time of beginning the celecoxib
treatment, the abdominal aortas of a separate group of mice not
treated with celecoxib were analyzed after 3 weeks of AngII
infusion (Figure 2A). Although the difference was not statistically
significant, the incidence of AAAs following 3 weeks of AngII
infusion was 67% (3 Wks AngII), as compared to a 36% AAA
incidence in mice that received an additional 5 weeks of celecoxib
treatment (Figure 2A). These findings suggest that beginning
celecoxib treatment after significant AAA formation has occurred
is effective in reducing the incidence of disease.

Figure 2. COX-2 inhibitor treatment initiated 3 weeks after
beginning AngII infusion effectively reduces AAA progression
in ApoE-deficient mice. (A) AAA incidence was determined at
necropsy following 3 (3 Wks AngII) or 8 weeks (Control and Celecoxib)
of AngII infusion. (B) The maximal external diameter or (C) AAA
classification of the suprarenal aorta following 3 (3 Wks AngII) or 8
weeks (Control and Celecoxib) of AngII infusion. For aortic diameter,
results depict mean 6 SEM. AAA incidence and diameter: 3 Wks AngII
n = 12, Control n = 13, Celecoxib n = 14. P values were determined for
incidence data using Fisher’s exact test and an unpaired two-tailed ttest for aortic diameter. * indicates P,0.05.
doi:10.1371/journal.pone.0044369.g002

COX-2 inhibitor treatment initiated during late-stage
AAA progression reduces AAA severity
We also examined the effect on abdominal aorta diameter that
resulted from initiating celecoxib treatment after advanced AAA
formation. Celecoxib treatment was initiated 3 weeks after
beginning the AngII infusion and was continued for the remaining
5 weeks of the infusion. As shown in Figure 2B, celecoxib
treatment significantly reduced the external diameter of the
abdominal aorta and decreased the severity of the vascular
pathology (Figure 2C), as compared to 8-week AngII-infused mice
on control diet. The severity of aneurysmal pathology at the time
of beginning celecoxib was estimated by analyzing aortic diameter
in a separate group of untreated mice after a 3 week AngII
infusion. The aortic diameter after 3 weeks of AngII infusion
showed an intermediate level of severity between the control and
celecoxib treatment groups (Figure 2 B–C). These findings indicate
PLOS ONE | www.plosone.org

that celecoxib treatment initiated after the development of
significant aneurysmal pathology effectively reduced or reversed
the progression of disease severity.
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lamina between the medial layers with the greatest COX-2
expression being in cells outside of the external elastic lamina
(Figure 4E). In contrast to the sections containing an AAA, COX2 expression was not observed in the abdominal aorta of mice
without evidence of aneurysmal remodeling (Figure 4F). These
findings indicate that during aneurysmal progression COX-2 was
preferentially expressed in cells involved in remodeling of the outer
smooth muscle layer.

Effect of COX-2 inhibitor treatment on expression of
markers of inflammation
We have previously shown that the initial stage of AAA
development during the first week of AngII infusion is characterized by increased macrophage infiltration and increased expression of inflammatory cell recruitment chemokines [4]. In the
current study, we examined the effect of celecoxib treatment
initiated during early-stage AAA progression on macrophagedependent inflammation in the abdominal aorta. Mice that were
infused with AngII for 6 weeks and provided a diet without
celecoxib were compared to mice that received celecoxib
containing diet beginning 1 week after the initiation of a 6-week
AngII infusion. The mRNA expression of neither the macrophage
marker CD68, the monocyte recruitment chemokine MCP-1, nor
the proinflammatory cytokine TNFa was significantly different in
the abdominal aortas between control and celecoxib-treated mice
(Figure 3 A–C). The macrophage-dependent inflammation that
occurs following AAA formation has been shown to result in the
increased expression of MMPs [1,11,12]. We examined the effect
of celecoxib treatment on the mRNA expression of MMP-2 and
MMP-9 in the abdominal aorta. Although the mRNA expression
of MMP-2 was significantly reduced in the abdominal aorta of
mice that received celecoxib (Figure 3D), there was no effect on
the expression of MMP-9 (Figure 3E). In addition, there was no
effect of celecoxib treatment on mRNA expression of CD34
(Figure 3F), which has been shown to be a marker of mast cells in
mice [13]. These findings indicate that the effectiveness of COX-2
inhibition in reducing the progression of AAAs was not associated
with reduced characteristics of inflammation.

SMCs involved in aneurysmal remodeling express
characteristics of altered differentiation
The differentiated phenotype of smooth muscle cells of the
medial layer has been defined by expression of contractile proteins.
The contractile protein most often used to identify differentiated
smooth muscle cells is smooth muscle a-actin, and is the most
highly expressed actin in aortic smooth muscle [16]. We examined
a-actin expression by immunohistochemistry in the abdominal
aorta during AAA progression. In the abdominal aorta of mice
with early-stage disease, aneurysmal pathology is primarily
localized to one side of the aorta (Figure 5A). Although a-actin
expression is observed throughout the medial layer of the aorta,
the expression in cells involved in the aneurysmal remodeling is
more diffuse than the concentrated expression observed on the
uninvolved side of the aorta (Figure 5B). The diffuse a-actin
expression is most evident in cells that appear outside of the
external elastic lamina, suggesting increased migration of SMCs
from the outer muscle layer (Figure 5C).
Vascular remodeling that results from increased SMC migration
contributes to the development of cardiovascular disease. Changes
in the SMC phenotype that allow for increased migration are
associated with increased production of extracellular matrix
components, particularly hyaluronic acid [17,18]. We used a
specific binding protein for histological detection of hyaluronic
acid in the abdominal aorta following AngII infusion. In addition
to detecting hyaluronic acid in cells dispersed throughout the
AAAs (Figure 5D), areas adjacent to the early AAAs where medial
layers remain intact contained cells with concentrated expression
of hyaluronic acid (Figure 5D insert). These hyaluronic acid
expressing cells appear on the luminal side of the external elastic
lamina in the medial smooth muscle layer.

Increased expression of COX-2 is localized to SMCs in
areas of aneurysmal remodeling
With the lack of a role for COX-2-dependent inflammation, we
examined the abdominal aorta microscopically to identify
pathological changes in resident cells of the vascular wall during
early aneurysm progression. The development of hematomas in
the wall of the abdominal aorta occurs early in the course of AngII
infusion [10]. In our current studies, we observed the occurrence
of hematomas in the abdominal aorta prior to evidence of
significant adventitial remodeling (Figure 4A). The regions of the
abdominal aorta with evidence of a hematoma consistently
showed the highest level of COX-2 expression, as determined by
immunohistochemistry (Figure 4B). The cells with the greatest
level of COX-2 expression were localized to the outer layer of
smooth muscle adjacent to the hematoma (Figure 4B). In a subset
of COX-2 expressing SMCs, a ring of concentrated expression
around individual nuclei was evident (Figure 4B), indicating
perinuclear expression, a known feature of COX-2 expression that
is observed after exposure to potent inducers of COX-2 expression
[14]. Therefore, at an early-stage of AAA development, COX-2
was highly expressed in SMCs of the outer medial layer prior to
detection of aneurysmal remodeling.
The progression of AngII-induced AAAs results in the
asymmetrical expansion of vascular wall remodeling that involves
preferentially one side of the aorta [15]. Using immunohistochemistry, we examined COX-2 expression in the abdominal
aorta of mice with early-stage aneurysmal remodeling. As shown
in Figure 4C, COX-2 expression was primarily detected in cells
adjacent to the aneurysmal pathology, rather than smooth muscle
cells of the uninvolved aorta on the side of the vessel away from the
AAA. The COX-2 expression was concentrated in multiple layers
of disorganized cells outside of the media and in the remodeled
adventitia (Figure 4D). The highest magnification shows elastic
PLOS ONE | www.plosone.org

COX-2 inhibitor treatment alters expression of SMC
differentiation markers
The de-differentiation of SMCs is characterized by reduced
mRNA expression of proteins contributing to contractile function
and increased gene expression leading to the production of
proteins that contribute to a synthetic phenotype [19]. We
examined the effect of celecoxib treatment on mRNA expression
of the contractile protein a-actin in the abdominal aorta of mice
infused with AngII. As compared to mice on control diet, a-actin
mRNA expression was significantly increased in mice that received
celecoxib treatment that began 1 week following the initiation of a
6-week AngII infusion (Figure 6A). As a marker of SMC dedifferentiation, we quantitated the mRNA expression of hyaluronic acid synthase 2 (HAS-2), which is primarily responsible for the
synthesis of hyaluronic acid in smooth muscle [20,21]. As
compared to mice on control diet, HAS-2 expression in the
abdominal aorta was significantly decreased in mice treated with
celecoxib beginning 1 week following the initiation of a 6-week
AngII infusion (Figure 6B). We also determined the effect of
celecoxib treatment that was started 3 weeks following the
initiation of an 8-week AngII infusion. As compared to mice on
control diet, a-actin expression in the abdominal aorta was
5
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Figure 3. COX-2 inhibitor treatment does not alter macrophage-dependent inflammation. Abdominal aorta was collected at necropsy for
control or celecoxib-treated mice beginning 1 week after initiating a 6-week AngII infusion. Real-time PCR quantitation of mRNA expression of (A) the
macrophage marker CD68, (B) the monocyte recruitment chemokine MCP-1, (C) the proinflammatory cytokine TNFa, (D–E) metalloproteinases
(MMPs) 22 and 29, and (F) the mast cell marker CD34. Expression levels of the gene of interest were normalized to HPRT mRNA levels. Results
indicate mean 6 SEM and the number of mice in each group is provided within the graphs. P values were determined using an unpaired two-tailed ttest. * indicates P,0.05.
doi:10.1371/journal.pone.0044369.g003

infusion (Figure 1 A–C). Furthermore, the AAA incidence and
severity after completion of the celecoxib treatment was similar to
that of mice that were not treated with celecoxib and infused with
AngII for 1 week (Figure 1 A–C). Therefore, these data suggest
that the final 5 weeks of the celecoxib treatment limited
progression of the AAA incidence and severity to the level that
occurred at the time of beginning the celecoxib treatment.
We also examined the effectiveness of COX-2 inhibition that
was started at a late-stage of AAA formation. For this study,
celecoxib treatment was started 3 weeks after initiating an 8 week
AngII infusion. With the prolonged continuous exposure to AngII
for 8 weeks and the potential for an unacceptable level of mortality
prior to completion of the study, the AngII infusion rate was
reduced from 1 to 0.75 mg/kg/min. In order to determine the
level of pathology at the time of beginning the celecoxib treatment,
we examined aneurysm formation in mice not receiving celecoxib
and infused with AngII for 3 weeks. At this 3 week time-point, the
majority of mice showed evidence of an AAA resulting in an
overall AAA incidence of 67% (Figure 2A). Beginning celecoxib
after 3 weeks of AngII infusion significantly reduced AAA
incidence and severity when evaluated after an additional 5 weeks
of AngII infusion, as compared to mice on control diet infused

significantly greater in mice receiving celecoxib during the final 5
weeks of the AngII infusion (Figure 6C). These findings indicate
that the effectiveness of celecoxib in reducing the progression of
AAAs was associated with increased expression of a-actin and
reduced HAS-2 expression, characteristics that are consistent with
maintenance of a differentiated SMC phenotype.

Discussion
In the current report, we show that beginning administration of
the COX-2 inhibitor celecoxib at an early-stage of AAA
development is highly effective at reducing progression of the
disease in ApoE-deficient mice. We have previously reported that
COX-2 gene expression is increased early in the course of AngIIinduced AAA development with significant induction being first
detected by 3 days after beginning the AngII infusion [4]. In our
current studies which examined the effect of beginning celecoxib
treatment 1 week after the start of the AngII infusion, effective
COX-2 inhibition would therefore not be expected to occur until
after the initial induction of COX-2 expression. This 1 week post
AngII infusion celecoxib treatment significantly reduced AAA
incidence and severity when analyzed at completion of a 6-week
PLOS ONE | www.plosone.org
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Figure 4. Histological analysis of the abdominal aorta during aneurysm progression. (A) Analysis of abdominal aorta containing a
hematoma following histochemical staining by H&E. (B) Immunohistochemical analysis of COX-2 expression in abdominal aorta adjacent to
hematoma. COX-2 expression in cells of the outer layers of a well-defined tunica media. Arrows indicate medial cells with concentrated expression of
COX-2 surrounding individual nuclei. (C) COX-2 expression in abdominal aorta with adventitial aneurysmal remodeling. COX-2 expression is
concentrated on the side of the aorta with aneurysmal remodeling without detectable expression on the non-involved side of the aorta (1006
magnification). (D) COX-2 expression in cells just outside of the medial layer into a region between the media and the remodeled adventitia (2006
magnification). (E) Cells with the greatest COX-2 expression are localized on the outer side of the external elastic lamina of the tunica media (4006
magnification). (F) Immunohistochemical analysis of COX-2 expression in abdominal aorta without aneurysmal pathology (4006 magnification).
Arrows indicate regions with concentrated COX-2 expression. Brown staining from DAB indicates COX-2 and sections are counterstained with
hematoxylin (blue).
doi:10.1371/journal.pone.0044369.g004

study with the greater levels of mortality, death of the mice
occurred throughout the course of the AngII infusion [24]. The
wide range of rupture incidence has been suggested to be the result
of studies using different aged mice, where mice greater than 6
months of age show a significantly higher mortality than the 10%
incidence that occurs in 2-month-old mice [10,24]. In the current
studies which utilized 4 month-old ApoE-deficient mice, the
celecoxib-treated group of mice received the COX-2 inhibitor
beginning 1 week after the initiation of AngII infusion. The
mortality that occurred after the first week of AngII infusion was
compared between mice receiving control or celecoxib containing
diet. Our findings show that celecoxib treatment beginning 1 week
after the initiation of AngII infusion significantly reduced the
incidence of mortality during the final 5 weeks of the infusion
(Figure 1C). Therefore, COX-2 inhibitor treatment that is started

with AngII for 8 weeks (Figure 2 A–C). Therefore, although
significant AAA pathology was present at the time of beginning
celecoxib, COX-2 inhibition effectively reduced further late-stage
progression of the disease.
The primary clinical significance for patients developing aortic
aneurysms is the increased risk of aortic rupture, which has a 90%
mortality rate [22]. Once formed, small AAAs gradually expand
over multiple years increasing the risk of eventual rupture and
resulting mortality [23]. An effective pharmacological treatment
for AAAs must therefore reduce both the progression of
aneurysmal remodeling and the resulting aortic rupture. The
AngII infusion model is associated with an increase in mortality
that results from rupture of the aorta. The incidence of rupture
and resulting morality that has been reported in this model using
ApoE-deficient mice has varied from 10% to 47% [10,24]. In the

PLOS ONE | www.plosone.org
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Figure 5. Immunohistochemical analysis of markers of smooth muscle cell differentiation and de-differentiation. (A) a-actin
expressing smooth muscle cells localize to the side of the abdominal aorta involved in aneurysmal remodeling (1006magnification). (B) As compared
to the non-involved aorta, a-actin expression is more diffuse (arrow) in the SMCs involved in aneurysmal remodeling (2006magnification). (C) a-actin
expression is localized to SMCs within the medial layer and to SMCs outside of the external elastic lamina (4006 magnification). (D) Hyaluronic acid
expression is localized throughout the AAA and in cells within the medial side of the external elastic lamina. The boxed area is shown within the insert
at 4006 magnification. Brown staining from DAB indicates a-actin or hyaluronic acid detection and sections are counterstained with hematoxylin
(blue).
doi:10.1371/journal.pone.0044369.g005

after initiation of the disease is effective for reducing both
aneurysmal remodeling and lethal aortic rupture.
We have previously shown that the inhibition of macrophagedependent inflammation is a prominent feature when COX-2 is
inactivated prior to initiating AngII infusion [4]. Therefore, we
expected that the effectiveness of COX-2 inhibition for reducing
AAAs and aortic rupture when started during the progressionstage of the disease would also correlate with reduced expression of
markers of inflammation. We measured mRNA expression of the
macrophage marker CD68, the macrophage recruitment chemokine MCP-1, and the pro-inflammatory cytokine TNFa (Figure 3
A–C). However, the effectiveness of COX-2 inhibition for
attenuating AAA progression was not associated with reduced
expression of these markers of macrophage-dependent inflammation.
AAA development is associated with increased expression of
MMPs, particularly MMP-2 and MMP-9 [25]. The increased
levels of MMP-9 in human aneurysmal tissue results from
expression by infiltrating macrophages whereas increased MMP2 expression is primarily derived from increased expression by
resident cells of the vascular wall [11,12,26,27]. Mouse models of
AAAs have shown a similar role for MMP-9 expression being
dependent on macrophage infiltration and MMP-2 being derived
from mesenchymal cells [1,28]. Furthermore, the effectiveness of
mPGES-1 deficiency in reducing AngII-induced AAAs is not
PLOS ONE | www.plosone.org

associated with attenuated macrophage-dependent inflammation,
but does correlate with reduced activity of MMP-2 and not MMP9 [5]. Similarly, our current findings show that the effectiveness of
COX-2 inhibition for reducing AAA progression was not
associated with decreased mRNA expression of MMP-9 or
attenuated macrophage-dependent inflammation (Figure 3, A–C,
E). In contrast to the effect on MMP-9 expression, celecoxib
significantly reduced mRNA expression of MMP-2 (Figure 3D).
Increased MMP-2 expression occurs during phenotypic modulation of SMCs and AngII increases the expression of MMP-2 that
occurs during SMC de-differentiation [29,30,31]. SMC dedifferentiation is associated with AAA formation and increased
SMC expression of MMP-2 is an early characteristic of the disease
[25,32]. Our finding that celecoxib significantly reduced expression of MMP-2 suggests that COX-2 may contribute to SMC dedifferentiation during the progression of AngII-induced AAAs.
An altered level of differentiation of SMCs in the abdominal
aorta is an early characteristic of AAA formation. Aortic aneurysm
development in humans and animal models of the disease is
associated with an altered SMC phenotype resulting in reduced
expression of contractile proteins [25]. Mutations in SMC
contractile proteins have also been identified as causative factors
contributing to inherited forms of aortic aneurysms [33,34,35].
Mutations in signaling pathways that cause excessive de-differentiation of aortic SMCs also contribute to inherited forms of aortic
8
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outside of a well-defined medial layer adjacent to aneurysmal
remodeling (Figure 4 C–E). These regions involved in the
remodeling also showed evidence of disorganized cells expressing
a variable level of a-actin (Figure 5 A–C). SMCs on the medial
side of the external elastic lamina adjacent to AAAs also produced
hyaluronic acid (Figure 5D), a characteristic of SMCs following
de-differentiation [17]. The effectiveness of celecoxib treatment for
attenuating AAA progression was associated with increased
mRNA expression of a-actin and decreased expression of
hyaluronic acid synthase, characteristics associated with maintenance of a differentiated SMC phenotype (Figure 6). These
findings suggest that COX-2 contributes to the de-differentiation
of medial SMCs thereby enhancing a migratory phenotype which
promotes vascular remodeling during AAA progression.
The expression of COX-2 is critical to the development of
AngII-induced AAAs. Our current findings show that COX-2
protein expression in the abdominal aorta is detected in the
smooth muscle cell layer of the vessel. Although these findings
suggest that the effectiveness of celecoxib in reducing AAA
progression may result from inhibiting the activity of COX-2 in
SMCs of the vessel, the current studies did not confirm the
causative action of COX-2 expressed specifically by the SMCs.
Identification of the cell type responsible for the expression of
COX-2 contributing to AAA development may be addressed most
definitively by future studies utilizing cell-type specific COX-2deficient mice.
There are some limitations of the current study that should be
noted. First, although the effectiveness of celecoxib in reducing
AAA expression correlated with increased expression of the SMC
differentiation marker a-actin, our findings have not confirmed a
causative role for increased SMC differentiation as a mechanism
contributing to the effectiveness of COX-2 inhibition. The effect
on AAAs that resulted from direct manipulation of SMC
differentiation would be required to prove causation of this
mechanism. Second, our current findings show that following
AngII infusion COX-2 protein expression in the abdominal aorta
is detected in the smooth muscle layer of the vessel. Although these
findings suggest the importance of COX-2 expressed by SMCs,
confirmation of the specific cell type involved would require the
use of cell-type specific COX-2-deficient mice. Third, the AngIIinduced mouse model has been widely utilized to examine the role
of different mechanisms contributing to AAAs. However, there are
a variety of animal models of AAA and no single model may
accurately reproduce AAA development in humans. Therefore,
the significance of our current findings in relation to mechanisms
contributing to human AAAs is currently not known.
The chronic use of COX-2 inhibitors has been associated with
increased risk of adverse cardiovascular effects in humans.
Although the COX-2 inhibitor rofecoxib was withdrawn from
the market because of these effects, celecoxib remains available
and is widely used in the United States for the treatment of
arthritis. While the level of risk from adverse cardiovascular effects
that results from celecoxib is controversial, a number of studies
suggest that the risk with celecoxib is lower than rofecoxib, and is
similar to that of commonly used nonselective COX inhibitors
[37,38,39]. However, when compared to placebo, the cardiovascular risk of celecoxib has been shown to increase with higher
doses, or the presence of preexisting cardiovascular disease [40].
The safety of different doses of celecoxib in patients with
preexisting cardiovascular disease is currently being studied in
the Prospective Randomized Evaluation of Celecoxib Integrated
Safety versus Ibuprofen or Naproxen (PRECISION) trial [41].
Understanding the level of risk of celecoxib in patients with
cardiovascular disease is needed before determining the feasibility

Figure 6. COX-2 inhibitor treatment maintains mRNA expression of markers of differentiated smooth muscle. Real-time PCR
quantitation of (A) a-actin or (B) hyaluronic acid synthase-2 mRNA
expression in the abdominal aorta. Mice were provided control or
celecoxib containing diet beginning 1 week after initiating a 6-week
AngII infusion. (C) Quantitation of a-actin mRNA expression in the
abdominal aorta of mice provided control or celecoxib containing diet
beginning 3 weeks after initiating an 8-week AngII infusion. Expression
levels of the gene of interest were normalized to HPRT mRNA levels.
Results indicate mean 6 SEM and the number of mice in each group is
provided within the graphs. P values were determined using an
unpaired two-tailed t-test. * indicates P,0.05.
doi:10.1371/journal.pone.0044369.g006

aneurysm development [36]. The development of a hematoma in
the abdominal aorta is an early event following AngII infusion
prior to significant vascular wall remodeling [10]. In the current
report, we examined COX-2 expression in the abdominal aorta
from mice showing evidence of a hematoma (Figure 4A). As
determined by immunohistochemistry, the outer layer of SMCs
adjacent to hematomas expressed COX-2 (Figure 4B). COX-2
expression was also concentrated in regions of abdominal aorta
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of future clinical trials for evaluating the therapeutic potential of
celecoxib as a treatment for AAAs.
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